GnRH Agonist Pretreatment in Hysteroscopic Myomectomy
- Registration Number
- NCT01873378
- Lead Sponsor
- Azienda Ospedaliera S. Maria della Misericordia
- Brief Summary
The primary outcome of this study is to assess if the GnRHa administration before cold loop hysteroscopic myomectomy contributes to accomplish the treatment in only one surgical procedure. Moreover, we will investigate the intraoperative influence of such pharmacologic therapy in terms of distension liquid absorption and duration of the procedures.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 84
Inclusion Criteria
- submucous myoma diagnosed by vaginal ultrasonography and confirmed by diagnostic hysteroscopy
- premenopausal status
Exclusion Criteria
- present or past history of cancer
- pregnancy
- presence of associated multiple polyps
- presence of > 2 myomas
- associated nonhysteroscopic surgical procedures
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description GnRH agonist pretreatment Triptorelin 3.75 mg triptorelin 3.75 mg, im, monthly, three times
- Primary Outcome Measures
Name Time Method To assess if the GnRHa administration before cold loop hysteroscopic myomectomy contributes to accomplish the treatment in only one surgical procedure. Just finished the surgical procedure.
- Secondary Outcome Measures
Name Time Method Minutes (surgical procedure time), milliliters (fluid absorption during the procedure). Just finished the surgical procedure.
Trial Locations
- Locations (1)
Arbor Vitae Endoscopic Centre
🇮🇹Rome, Italy